| # | Drug | Count |
|---|---|---|
| 0 | RITUXIMAB | 79 |
| 1 | CYCLOPHOSPHAMIDE | 78 |
| 2 | CYCLOPHOSPHAMIDE FOR INJECTION | 78 |
| 3 | CYCLOPHOSPHAMIDE INJECTION, SOLUTION | 78 |
| 4 | PREDNISONE | 51 |
| 5 | DOXORUBICIN | 48 |
| 6 | ETOPOSIDE | 45 |
| 7 | PREDNISOLONE | 20 |
| 8 | PREDNISOLONE ORAL | 20 |
| 9 | PREDNISOLONE ORAL SOLUTION | 20 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | EPCORITAMAB-BYSP | 5 | 0.0037 |
| 1 | SUTIMLIMAB-JOME | 1 | 0.0031 |
| 2 | ETOPOSIDE PHOSPHATE | 4 | 0.0024 |
| 3 | LISOCABTAGENE MARALEUCEL | 2 | 0.0023 |
| 4 | MITOXANTRONE HYDROCHLORIDE | 10 | 0.0016 |
| 5 | AXICABTAGENE CILOLEUCEL | 15 | 0.0015 |
| 6 | PURIXAN | 1 | 0.0013 |
| 7 | BLEOMYCIN SULFATE | 7 | 0.0007 |
| 8 | PLERIXAFOR | 1 | 0.0007 |
| 9 | ETOPOSIDE | 45 | 0.0006 |
| # | Drug class | Count |
|---|---|---|
| 0 | Alkylating Drug [EPC] | 83 |
| 1 | CD20-directed Cytolytic Antibody [EPC] | 81 |
| 2 | Corticosteroid [EPC] | 74 |
| 3 | Topoisomerase Inhibitor [EPC] | 45 |
| 4 | Platinum-based Drug [EPC] | 24 |
| 5 | Thalidomide Analog [EPC] | 17 |
| 6 | Atypical Antipsychotic [EPC] | 16 |
| 7 | CD19-directed Chimeric Antigen Receptor [EPC] | 15 |
| 8 | Genetically-modified Autologous T Cells [EPC] | 15 |
| 9 | Proton Pump Inhibitor [EPC] | 14 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Classical Complement Pathway Inhibitor [EPC] | 1 | 0.0031 |
| 1 | CD19-directed Chimeric Antigen Receptor [EPC] | 15 | 0.0015 |
| 2 | Bispecific CD20-directed CD3 T Cell Engager [EPC] | 5 | 0.0012 |
| 3 | Hematopoietic Stem Cell Mobilizer [EPC] | 1 | 0.0007 |
| 4 | Topoisomerase Inhibitor [EPC] | 45 | 0.0006 |
| 5 | Alkylating Drug [EPC] | 83 | 0.0003 |
| 6 | CD20-directed Cytolytic Antibody [EPC] | 81 | 0.0003 |
| 7 | Blood Viscosity Reducer [EPC] | 1 | 0.0002 |
| 8 | Selective T Cell Costimulation Blocker [EPC] | 1 | 0.0002 |
| 9 | CD52-directed Cytolytic Antibody [EPC] | 3 | 0.0002 |